201 related articles for article (PubMed ID: 32051301)
21. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
22. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
23. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
24. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
25. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cho YY; Cho SI
Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
[TBL] [Abstract][Full Text] [Related]
26. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
Gitt AK; Bramlage P; Schneider S; Tschöpe D
Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
[TBL] [Abstract][Full Text] [Related]
27. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
28. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
[TBL] [Abstract][Full Text] [Related]
29. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
Alemayehu B; Liu J; Rajpathak S; Engel SS
J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
[TBL] [Abstract][Full Text] [Related]
30. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
31. Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience.
Fisher SJ; Huang X; Pawaskar M; Witt EA; Rajpathak S; Shankar RR; Inzucchi SE
Endocrine; 2018 Jun; 60(3):435-444. PubMed ID: 29460218
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
33. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
35. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
36. Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.
Holbrook T; Tang Y; Das R; Shankar RR; Tunceli K; Williams J; Radican L; Holden SE; Morgan CL; Piercy J; Currie CJ
Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28544081
[TBL] [Abstract][Full Text] [Related]
37. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of combined therapy for type 2 diabetes.
Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
[TBL] [Abstract][Full Text] [Related]
39. Quality measure attainment in patients with type 2 diabetes mellitus.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Sheng Duh M; Lefebvre P
Am J Manag Care; 2014 Jan; 20(1 Suppl):s5-15. PubMed ID: 24512194
[TBL] [Abstract][Full Text] [Related]
40. Sulfonylurea monotherapy and emergency room utilization among elderly patients with type 2 diabetes.
Rajpathak SN; Fu C; Brodovicz K; Engel SS; Heaton PC
Diabetes Res Clin Pract; 2015 Sep; 109(3):507-12. PubMed ID: 26123984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
